Imatinib Mesylate FDA Link

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Also Known As:

Gleevec; Glivec; STI571; Alpha- (4- methyl- 1- piperazinyl)- 3'- ((4- (3- pyridyl)- 2- pyrimidinyl)amino)- p- tolu- p- toluidide; CGP 57148; CGP-57148; CGP57148B; Imatinib; Imatinib Methanesulfonate; ST 1571; ST1571; STI 571; STI-571; CGP57148; Mesylate, Imatinib; Methanesulfonate, Imatinib

Organic Chemicals: 140
- Amides: 2487
  - Benzamides: 115
    - Imatinib Mesylate: 9991
- Hydrocarbons: 1726
  - Cyclic Hydrocarbons: 96
    - Aromatic Hydrocarbons: 295
      - Benzene Derivatives: 17
        Benzoates: 430
        Benzamides: 115
        Imatinib Mesylate: 9991
- Carboxylic Acids: 986
  - Carbocyclic Acids
    - Benzoates: 430
      - Benzamides: 115
        Imatinib Mesylate: 9991
Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 521
    - Imatinib Mesylate: 9991
  - Piperazines: 26
    - Imatinib Mesylate: 9991

Anupma Jati Selected Research

Anupma Jati Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure